Browse ADCY5

Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein. Cell projection, cilium
Domain PF16214 Adenylyl cyclase N-terminal extracellular and transmembrane region
PF06327 Domain of Unknown Function (DUF1053)
PF00211 Adenylate and Guanylate cyclase catalytic domain
Function

Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling (PubMed:15385642, PubMed:26206488, PubMed:24700542). Mediates signaling downstream of ADRB1 (PubMed:24700542). Regulates the increase of free cytosolic Ca(2+) in response to increased blood glucose levels and contributes to the regulation of Ca(2+)-dependent insulin secretion (PubMed:24740569).

> Gene Ontology
 
Biological Process GO:0001678 cellular glucose homeostasis
GO:0001973 adenosine receptor signaling pathway
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0003014 renal system process
GO:0003091 renal water homeostasis
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007189 adenylate cyclase-activating G-protein coupled receptor signaling pathway
GO:0007190 activation of adenylate cyclase activity
GO:0007191 adenylate cyclase-activating dopamine receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007195 adenylate cyclase-inhibiting dopamine receptor signaling pathway
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007212 dopamine receptor signaling pathway
GO:0007626 locomotory behavior
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009306 protein secretion
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0019932 second-messenger-mediated signaling
GO:0019933 cAMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030104 water homeostasis
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0031279 regulation of cyclase activity
GO:0031281 positive regulation of cyclase activity
GO:0032147 activation of protein kinase activity
GO:0032844 regulation of homeostatic process
GO:0033500 carbohydrate homeostasis
GO:0033674 positive regulation of kinase activity
GO:0033762 response to glucagon
GO:0034199 activation of protein kinase A activity
GO:0034284 response to monosaccharide
GO:0035587 purinergic receptor signaling pathway
GO:0035588 G-protein coupled purinergic receptor signaling pathway
GO:0035773 insulin secretion involved in cellular response to glucose stimulus
GO:0042593 glucose homeostasis
GO:0042886 amide transport
GO:0043434 response to peptide hormone
GO:0045761 regulation of adenylate cyclase activity
GO:0045762 positive regulation of adenylate cyclase activity
GO:0045860 positive regulation of protein kinase activity
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0048871 multicellular organismal homeostasis
GO:0050708 regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0050878 regulation of body fluid levels
GO:0050885 neuromuscular process controlling balance
GO:0050891 multicellular organismal water homeostasis
GO:0050905 neuromuscular process
GO:0051339 regulation of lyase activity
GO:0051349 positive regulation of lyase activity
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0052652 cyclic purine nucleotide metabolic process
GO:0055074 calcium ion homeostasis
GO:0061178 regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071375 cellular response to peptide hormone stimulus
GO:0071377 cellular response to glucagon stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072522 purine-containing compound biosynthetic process
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901654 response to ketone
GO:1901655 cellular response to ketone
GO:1904321 response to forskolin
GO:1904322 cellular response to forskolin
Molecular Function GO:0004016 adenylate cyclase activity
GO:0008179 adenylate cyclase binding
GO:0009975 cyclase activity
GO:0016829 lyase activity
GO:0016849 phosphorus-oxygen lyase activity
GO:0046982 protein heterodimerization activity
GO:0097110 scaffold protein binding
Cellular Component GO:0005929 cilium
GO:0072372 primary cilium
> KEGG and Reactome Pathway
 
KEGG hsa04015 Rap1 signaling pathway
hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04062 Chemokine signaling pathway
hsa04114 Oocyte meiosis
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04270 Vascular smooth muscle contraction
hsa04540 Gap junction
hsa04611 Platelet activation
hsa04713 Circadian entrainment
hsa04723 Retrograde endocannabinoid signaling
hsa04724 Glutamatergic synapse
hsa04725 Cholinergic synapse
hsa04726 Serotonergic synapse
hsa04727 GABAergic synapse
hsa04728 Dopaminergic synapse
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04911 Insulin secretion
hsa04912 GnRH signaling pathway
hsa04913 Ovarian steroidogenesis
hsa04914 Progesterone-mediated oocyte maturation
hsa04915 Estrogen signaling pathway
hsa04916 Melanogenesis
hsa04918 Thyroid hormone synthesis
hsa04921 Oxytocin signaling pathway
hsa04970 Salivary secretion
hsa04971 Gastric acid secretion
hsa04972 Pancreatic secretion
hsa04976 Bile secretion
hsa00230 Purine metabolism
Reactome R-HSA-991365: Activation of GABAB receptors
R-HSA-170660: Adenylate cyclase activating pathway
R-HSA-170670: Adenylate cyclase inhibitory pathway
R-HSA-400042: Adrenaline,noradrenaline inhibits insulin secretion
R-HSA-445717: Aquaporin-mediated transport
R-HSA-111996: Ca-dependent events
R-HSA-111997: CaM pathway
R-HSA-111933: Calmodulin induced events
R-HSA-1489509: DAG and IP3 signaling
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-186763: Downstream signal transduction
R-HSA-212718: EGFR interacts with phospholipase C-gamma
R-HSA-418594: G alpha (i) signalling events
R-HSA-418555: G alpha (s) signalling events
R-HSA-418597: G alpha (z) signalling events
R-HSA-112040: G-protein mediated events
R-HSA-977444: GABA B receptor activation
R-HSA-977443: GABA receptor activation
R-HSA-388396: GPCR downstream signaling
R-HSA-163359: Glucagon signaling in metabolic regulation
R-HSA-381676: Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
R-HSA-5610787: Hedgehog 'off' state
R-HSA-168256: Immune System
R-HSA-997269: Inhibition of adenylate cyclase pathway
R-HSA-168249: Innate Immune System
R-HSA-163685: Integration of energy metabolism
R-HSA-1430728: Metabolism
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-111885: Opioid Signalling
R-HSA-163615: PKA activation
R-HSA-164378: PKA activation in glucagon signalling
R-HSA-111931: PKA-mediated phosphorylation of CREB
R-HSA-112043: PLC beta mediated events
R-HSA-167021: PLC-gamma1 signalling
R-HSA-422356: Regulation of insulin secretion
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-5358351: Signaling by Hedgehog
R-HSA-186797: Signaling by PDGF
R-HSA-166520: Signalling by NGF
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-432040: Vasopressin regulates renal water homeostasis via Aquaporins
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADCY5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADCY5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADCY5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1510.548
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3940.397
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.020.957
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1610.864
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3570.86
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0780.977
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.3620.0109
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.0980.00924
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5420.543
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2830.854
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0570.978
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2310.312
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADCY5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.76.8-3.11
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADCY5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADCY5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADCY5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADCY5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADCY5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADCY5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADCY5
Nameadenylate cyclase 5
Aliases AC5; FDFM; ATP pyrophosphate-lyase 5; adenylate cyclase type V; adenylyl cyclase 5; Adenylate cyclase type 5
Chromosomal Location3q21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADCY5 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ADCY5.
ID Name Drug Type Targets #Targets
DB02587ColforsinSmall MoleculeADCY2, ADCY5, CFTR3
DB068432',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATESmall MoleculeADCY2, ADCY52
DB09121AurothioglucoseSmall MoleculeADCY1, ADCY2, ADCY53